Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.43 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.42 |
| ▸ | MMP2 | P08253 | 1/20 | 0.42 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.42 |
| ▸ | COMT | P21964 | 1/20 | 0.42 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.42 |
| ▸ | METAP2 | P50579 | 1/20 | 0.42 |
| ▸ | METAP1 | P53582 | 1/20 | 0.42 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.42 |
| ▸ | TLR7 | Q9NYK1 | 5/20 | 0.41 |
| ▸ | SPR | P35270 | 1/20 | 0.37 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.37 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.37 |
| ▸ | IDO1 | P14902 | 1/20 | 0.37 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28826447 | 0.81 | KDM4E (0.35) | TSHRALDH1A1L3MBTL1TLR7HSP90AA1 | |
| SCHEMBL2459394 | 0.80 | KDM4E (0.47) | TSHRALDH1A1L3MBTL1KDM4ECYP3A4 | |
| SCHEMBL8847897 | 0.80 | EGLN2 (0.44) | EGLN2FTOTSHRALDH1A1L3MBTL1 | |
| Hydrochloric Acid SCHEMBL5730020 | 0.79 | KMT2A (0.38) | TSHRALDH1A1L3MBTL1TLR7HSP90AA1 | |
| SCHEMBL4307144 | 0.78 | TLR7 (0.44) | EGLN2FTOTSHRALDH1A1L3MBTL1 | |
| SCHEMBL30452318 | 0.78 | EGLN2 (0.51) | EGLN2FTOTSHRALDH1A1L3MBTL1 | |
| SCHEMBL324349 | 0.78 | EGLN2 (0.51) | EGLN2FTOTSHRALDH1A1L3MBTL1 | |
| SCHEMBL6454171 | 0.78 | GRM4 (0.41) | TSHRALDH1A1L3MBTL1TLR7HSP90AA1 | |
| SCHEMBL2240052 | 0.77 | NOS3 (0.54) | TSHRALDH1A1L3MBTL1METAP2KDM4E | |
| SCHEMBL13886916 | 0.77 | MAPT (0.38) | TSHRALDH1A1L3MBTL1KDM4ECYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240376513-A1 | ELECTROCHEMICAL BIOSENSOR, OR SENSING MEMBRANE FOR ELECTROCHEMICAL BIOSENSOR CONTAINING TRANSITION METAL COMPLEX OR OXIDATION-REDUCTION POLYMER | I-SENS, INC. (KR) | 2024-11-14 | — | — | US | disclosed |
| EP-4402140-A1 | HETEROARYL-LINKED ANALOGS AS MGLU5 NEGATIVE ALLOSTERIC MODULATORS AND METHODS OF MAKING AND USING THE SAME | Vanderbilt University (US) | 2024-07-24 | — | — | EP | disclosed |
| EP-4387609-A2 | ARYL SULFONYL (HYDROXY) PIPERIDINES AS CCR6 INHIBITORS | ChemoCentryx, Inc. (US) | 2024-06-26 | — | — | EP | disclosed |
| EP-4328232-A1 | ELECTROCHEMICAL BIOSENSOR, OR SENSING MEMBRANE FOR ELECTROCHEMICAL BIOSENSOR CONTAINING TRANSITION METAL COMPLEX OR OXIDATION-REDUCTION POLYMER | I-SENS, INC. (KR) | 2024-02-28 | — | — | EP | disclosed |
| US-11891389-B2 | PGDH inhibitors and methods of making and using | MYOFORTE THERAPEUTICS, INC. (US) | 2024-02-06 | — | — | US | disclosed |
| US-20230390274-A1 | INHALED FORMULATIONS OF PGDH INHIBITORS AND METHODS OF USE THEREOF | MYOFORTE THERAPEUTICS, INC. | 2023-12-07 | — | — | US | disclosed |
| EP-4228650-A1 | INHALED FORMULATIONS OF PGDH INHIBITORS AND METHODS OF USE THEREOF | Epirium Bio Inc. (US) | 2023-08-23 | — | — | EP | disclosed |
| WO-2023043833-A1 | HETEROARYL-LINKED ANALOGS AS MGLU5 NEGATIVE ALLOSTERIC MODULATORS AND METHODS OF MAKING AND USING THE SAME | VANDERBILT UNIVERSITY (US) | 2023-03-23 | — | — | WO | disclosed |
| WO-2023023532-A2 | ARYL SULFONYL (HYDROXY) PIPERIDINES AS CCR6 INHIBITORS | CHEMOCENTRYX, INC. (US) | 2023-02-23 | — | — | WO | disclosed |
| CN-115335043-A | PGDH inhibitors and methods of making and using | 迈欧伏特治疗公司 | 2022-11-11 | — | — | CN | disclosed |
| EP-2227466-A2 | HETEROARYL-SUBSTITUTED PIPERIDINES | Bayer Schering Pharma Aktiengesellschaft (DE) | 2010-09-15 | — | — | EP | disclosed |
| WO-2010018458-A2 | PHENOL DERIVATIVES AND METHODS OF USE THEREOF | CRYSTALGENOMICS, INC. (KR) | 2010-02-18 | — | — | WO | disclosed |
| WO-2010018458-A2 | PHENOL DERIVATIVES AND METHODS OF USE THEREOF | CRYSTALGENOMICS, INC. (KR) | 2010-02-18 | — | — | WO | disclosed |
| WO-2009068214-A2 | HETEROARYL-SUBSTITUTED PIPERIDINES | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-06-04 | — | — | WO | disclosed |
| EP-1915375-A1 | DERIVATIVES OF 5-PYRIDINYL-1-AZABICYCLO[3.2.1]OCTANE, PREPARATION METHOD THEREOF AND USE OF SAME IN THERAPEUTICS | Sanofi-Aventis (FR) | 2008-04-30 | — | — | EP | disclosed |
| US-7214714-B2 | 20-hydroxyeicosatetraenoic acid production inhibitors | TAISHO PHARMACEUTICAL CO. LTD. (JP) | 2007-05-08 | — | — | US | disclosed |
| WO-2007020344-A1 | DERIVATIVES OF 5-PYRIDINYL-1-AZABICYCLO[3.2.1]OCTANE, PREPARATION METHOD THEREOF AND USE OF SAME IN THERAPEUTICS | SANOFI-AVENTIS (FR) | 2007-02-22 | — | — | WO | disclosed |
| WO-2004110351-A2 | HETEROCYCLIC COMPOUNDS FOR TREATING HEPATITIS C VIRUS | ANADYS PHARMACEUTICALS, INC. (US) | 2004-12-23 | — | — | WO | disclosed |
| US-20040121997-A1 | 20-hydroxyeicosatetraenoic acid production inhibitors | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2004-06-24 | — | — | US | disclosed |
| EP-1389611-A1 | 20-HYDROXYEICOSATETRAENOIC ACID PRODUCTION INHIBITORS | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2004-02-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11891389-B2 | PGDH inhibitors and methods of making and using | HPGD, HPGDS, PTGS1 | EGLN2 142/4885FTO 2262/4885TSHR 4152/4885 |
| US-20040121997-A1 | 20-hydroxyeicosatetraenoic acid production inhibitors | PTGS1, PTGIS, ALOX5 | EGLN2 285/4885FTO 1381/4885TSHR 2450/4885 |
| US-20230390274-A1 | INHALED FORMULATIONS OF PGDH INHIBITORS AND METHODS OF USE THEREOF | HPGD, HPGDS, GCDH | EGLN2 80/4885FTO 1858/4885TSHR 4186/4885 |
| US-20240376513-A1 | ELECTROCHEMICAL BIOSENSOR, OR SENSING MEMBRANE FOR ELECTROCHEMICAL BIOSENSOR CONTAINING TRANSITION METAL COMPLEX OR OXIDATION-REDUCTION POLYMER | OXA1L, PDK1, SLC2A3 | EGLN2 3204/4885FTO 860/4885TSHR 399/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.